L655,240, acting as a competitive BACE1 inhibitor, efficiently decreases β-amyloid peptide production in HEK293-APPswe cells

Acta Pharmacologica Sinica

Volumn 33, Issue 12, 2012, Pages 1459-1468

  Lu, Qin ^a   Chen, Wu Yan ^b   Zhu, Zhi Yuan ^b   Chen, Jing ^b   Xu, Ye Chun ^b   Kaewpet, Morakot ^c   Rukachaisirikul, Vatcharin ^c   Chen, Li Li ^b   Shen, Xu ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

amyloid peptide; Alzheimer's disease; BACE1; HEK293 APPswe cells; L655,240

Indexed keywords

3 [1 (4 CHLOROBENZYL) 5 FLUORO 3 METHYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAM17 PROTEIN; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BETA SECRETASE 1; GAMMA SECRETASE; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CONTROLLED STUDY; DRUG SELECTIVITY; ENZYMATIC ASSAY; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; ASPARTIC ACID PROTEASES; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL SURVIVAL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELLS; HUMANS; INDOLES; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; SMALL MOLECULE LIBRARIES; SURFACE PLASMON RESONANCE; TRANSFECTION;

EID: 84870802035     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.74     Document Type: Article

References (50)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362: 329-44
2. Wollen KA. Alzheimer' disease: the pros and cons of phamaceutical, nutritional, botanical, and stimulatory therapies, with a discussionof treatment strategies from the perspective of patients and practitioners.Altern Med Rev 2010; 15: 223-44
3. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE.Efficacy and safety of donepezil, galantamine, and rivastigmine forthe treatment of Alzheimer's disease: a systematic review and metaanalysis.Clin Interv Aging 2008; 3: 211-25
4. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia.Cochrane Database Syst Rev 2006; (2): CD003154
5. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K,et al. Effects of brain-penetrating ACE inhibitors on Alzheimer diseaseprogression. Neurology 2004; 63: 1324-5
6. Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers andcognitive function in elderly people: results from the Canadian Studyof Health and Aging. Cmaj 1999; 161: 501-6
7. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects ofNSAIDs on the development of Alzheimer disease. Neurology 2008;70: 1672-7
8. Li X, Bo H, Zhang XC, Hartsuck JA, Tang J. Predicting memapsin 2(beta-secretase) hydrolytic activity. Protein Sci 2010; 19: 2175-85
9. Cole SL, Vassar R. The basic biology of BACE1: a key therapeutictarget for Alzheimer's disease. Curr Genomics 2007; 8: 509-30
10. Citron M. Beta-secretase as a target for the treatment of Alzheimer'sdisease. J Neurosci Res 2002; 70: 373-9
11. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M,et al. BACE1 deficiency rescues memory deficits and cholinergicdysfunction in a mouse model of Alzheimer's disease. Neuron 2004;41: 27-33
12. Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, et al.Temporal memory deficits in Alzheimer's mouse models: rescue bygenetic deletion of BACE1. Eur J Neurosci 2006; 23: 251-60
13. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, et al. BACE1gene deletion prevents neuron loss and memory deficits in 5XFADAPP/PS1 transgenic mice. Neurobiol Dis 2007; 26: 134-45
14. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, et al.BACE1 is the major beta-secretase for generation of Abeta peptidesby neurons. Nat Neurosci 2001; 4: 233-4
15. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al.Mice deficient in BACE1, the Alzheimer's beta-secretase, have normalphenotype and abolished beta-amyloid generation. Nat Neurosci2001; 4: 231-2
16. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, ChenKS, et al. BACE knockout mice are healthy despite lacking the primarybeta-secretase activity in brain: implications for Alzheimer's diseasetherapeutics. Hum Mol Genet 2001; 10: 1317-24
17. Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, TrumbauerME, et al. Presenilin 1 is required for Notch1 and DII1 expression inthe paraxial mesoderm. Nature 1997; 387: 288-92
18. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletaland CNS defects in Presenilin-1-deficient mice. Cell 1997; 89: 629-39
19. Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS,Bernstein A. Mice lacking both presenilin genes exhibit earlyembryonic patterning defects. Genes Dev 1999; 13: 2801-10
20. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, et al. Structureof the protease domain of memapsin 2 (beta-secretase) complexedwith inhibitor. Science 2000; 290: 150-3
21. Kimura T, Shuto D, Hamada Y, Igawa N, Kasai S, Liu P, et al. Designand synthesis of highly active Alzheimer's beta-secretase (BACE1)inhibitors, KMI-420 and KMI-429, with enhanced chemical stability.Bioorg Med Chem Lett 2005; 15: 211-5
22. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabo B, et al. Thenovel beta-secretase inhibitor KMI-429 reduces amyloid beta peptideproduction in amyloid precursor protein transgenic and wild-type mice.J Neurochem 2006; 96: 533-40
23. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, et al. Oraladministration of a potent and selective non-peptidic BACE-1 inhibitordecreases beta-cleavage of amyloid precursor protein and amyloidbetaproduction in vivo. J Neurochem 2007; 100: 802-9
24. Iserloh U, Pan J, Stamford AW, Kennedy ME, Zhang Q, Zhang L, et al.Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1inhibitor. Bioorg Med Chem Lett 2008; 18: 418-22
25. Luo X, Yan R. Inhibition of BACE1 for therapeutic use in Alzheimer'sdisease. Int J Clin Exp Pathol 2010; 3: 618-28
26. Cole DC, Manas ES, Stock JR, Condon JS, Jennings LD, Aulabaugh A, et al. Acylguanidines as small-molecule beta-secretase inhibitors. JMed Chem 2006; 49: 6158-61
27. Baxter EW, Conway KA, Kennis L, Bischoff F, Mercken MH, Winter HL,et al. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (betasiteAPP cleaving enzyme): Use of structure based design to convert amicromolar hit into a nanomolar lead. J Med Chem 2007; 50: 4261-4
28. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, etal. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abetapathology and behavioral deficits in a mouse model of Alzheimer'sdisease. J Neurosci 2010; 30: 11157-66
29. Jeon SY, Bae K, Seong YH, Song KS. Green tea catechins as a BACE1(beta-secretase) inhibitor. Bioorg Med Chem Lett 2003; 13: 3905-8
30. Hwang EM, Ryu YB, Kim HY, Kim DG, Hong SG, Lee JH, et al. BACE1inhibitory effects of lavandulyl flavanones from Sophora flavescens.Bioorg Med Chem 2008; 16: 6669-74
31. Choi YH, Yoo MY, Choi CW, Cha MR, Yon GH, Kwon DY, et al. A newspecific BACE-1 inhibitor from the stembark extract of Vitis vinifera.Planta Med 2009; 75: 537-40
32. Zhu Z, Li C, Wang X, Yang Z, Chen J, Hu L, et al. 2,2′,4′- trihydroxychalconefrom Glycyrrhiza glabra as a new specific BACE1 inhibitorefficiently ameliorates memory impairment in mice. J Neurochem2009; 114: 374-85
33. Hall RA, Gillard J, Guindon Y, Letts G, Champion E, Ethier D, et al.Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methylindol-2-yl] 2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist. Eur J Pharmacol1987; 135: 193-201
34. Conroy DM, Sirois P. Early bronchial hyperresponsiveness followinginjection of sephadex beads in the guinea pig: involvement of plateletactivating factor and thromboxane A2. Inflammation 1999; 23: 437-48
35. Wainwright CL, Parratt Jr. The effects of L655,240, a selective thromboxaneand prostaglandin endoperoxide antagonist, on ischemia- andreperfusion-induced cardiac arrhythmias. J Cardiovasc Pharmacol1988; 12: 264-71
36. Xu Y, Li MJ, Greenblatt H, Chen W, Paz A, Dym O, et al. Flexibility ofthe flap in the active site of BACE1 as revealed by crystal structuresand molecular dynamics simulations. Acta Crystallogr D BiolCrystallogr 2011; 68: 13-25
37. Liu Q, Zhang Y, Lin Z, Shen H, Chen L, Hu L, et al. Danshen extract15,16-dihydrotanshinone I functions as a potential modulatoragainst metabolic syndrome through multi-target pathways. J SteroidBiochem Mol Biol 2010; 120: 155-63
38. Cachard-Chastel M, Lezoualc'h F, Dewachter I, Delomenie C, Croes S,Devijver H, et al. 5-HT4 receptor agonists increase sAPPalpha levels inthe cortex and hippocampus of male C57BL/6j mice. Br J Pharmacol2007; 150: 883-92
39. Wang L, Wang X, Chen J, Yang Z, Yu L, Hu L, et al. Activation of proteinserine/threonine phosphatase PP2Calpha efficiently prevents liverfibrosis. PLoS One 2010; 5: e14230
40. Kopan R, Goate A. A common enzyme connects notch signaling andAlzheimer's disease. Genes Dev 2000; 14: 2799-806
41. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neuraldevelopment. Nat Rev Neurosci 2006; 7: 93-102
42. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family membersas amyloid precursor protein alpha-secretases. J Neurosci Res 2003;74: 342-52
43. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, MastersCL, et al. Identification, biogenesis, and localization of precursors ofAlzheimer's disease A4 amyloid protein. Cell 1989; 57: 115-26
44. Tomita S, Kirino Y, Suzuki T. Cleavage of Alzheimer's amyloidprecursor protein (APP) by secretases occurs after O-glycosylation ofAPP in the protein secretory pathway. Identification of intracellularcompartments in which APP cleavage occurs without using toxicagents that interfere with protein metabolism. J Biol Chem 1998;273: 6277-84
45. Glenner GG, Wong CW. Alzheimer's disease: initial report of thepurification and characterization of a novel cerebrovascular amyloidprotein. Biochem Biophys Res Commun 1984; 120: 885-90
46. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloidhypothesis: a genetic perspective. Cell 2005; 120: 545-55
47. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesisfor Alzheimer's disease: an appraisal for the development oftherapeutics. Nat Rev Drug Discov 2011; 10: 698-712
48. Hardy J, Allsop D. Amyloid deposition as the central event in theaetiology of Alzheimer's disease. Trends Pharmacol Sci 1991; 12:383-8
49. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, et al.Identification of a novel aspartic protease (Asp 2) as beta-secretase.Mol Cell Neurosci 1999; 14: 419-27
50. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, etal. Mutant presenilins of Alzheimer's disease increase productionof 42-residue amyloid beta-protein in both transfected cells andtransgenic mice. Nat Med 1997; 3: 67-72.